In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
about
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrheaPrulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.Prulifloxacin: a new antibacterial fluoroquinolone.Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitisPrulifloxacin: clinical studies of a broad-spectrum quinolone agent.The antimicrobial armamentarium: evaluating current and future treatment options.Susceptibility of Urinary Tract Bacteria to Newer Antimicrobial DrugsPenetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery.Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans.Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers.Fabrication of stimulus-responsive diatom biosilica microcapsules for antibiotic drug deliverySusceptibility ofStreptococcus pneumoniaeclinical isolates to quinolones
P2860
Q24645660-4C71CDDB-085E-4BFF-ABA5-B9AF2F95A9E6Q34557698-1EB5F2DD-8B31-4A0F-AC3D-793FA73CDE75Q34564526-D2A50970-2E95-4AB9-BF69-92A1C2623CF2Q34585467-7751634E-4B77-4FEA-8E0C-D8746D9E4249Q34941542-D9DF1593-8344-49D0-8215-95BD5DD02F4AQ36264494-223494CE-C46D-45C5-9DF5-72DD6BF4FDC0Q36945004-6912ED2F-C9EB-45E1-9D0E-431F3A9CD5F0Q43949659-41F0C112-45DC-4F38-83EE-5ECF196AFF7DQ44704375-40C8DF4C-8E3F-4FD0-95ED-CE4CDD049F5DQ46514166-1BC7D45E-3DE4-4C0F-86A4-0413BD28EE08Q54181112-39C8F9D6-5704-4F46-ADBB-4868D07A0617Q54631603-F8DC97FB-3034-4A4F-A882-CAC479D75F5EQ57368986-A215E947-AB0E-428D-B21D-70A4437CF2BCQ58864097-7D89CF29-6543-43D7-A9DD-4D926C500BB8
P2860
In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro antibacterial activit ...... nd community Italian isolates.
@ast
In vitro antibacterial activit ...... nd community Italian isolates.
@en
type
label
In vitro antibacterial activit ...... nd community Italian isolates.
@ast
In vitro antibacterial activit ...... nd community Italian isolates.
@en
prefLabel
In vitro antibacterial activit ...... nd community Italian isolates.
@ast
In vitro antibacterial activit ...... nd community Italian isolates.
@en
P2860
P1476
In vitro antibacterial activit ...... and community Italian isolates
@en
P2093
Montanari MP
P2860
P304
P356
10.1128/AAC.45.12.3616-3622.2001
P407
P577
2001-12-01T00:00:00Z